2022 Chinese lymphoma Conference ｜ Professor Lin Tongyu: Chinese patients are not so rich, lymphoma drugs must be used by everyone

From July 7th to 8th, there were three great events in the lymphoma in the community of lymphoma — the opening of the 20122 China Lymphoma Conference, the first meeting of the first meeting of the Special Committee of the National Tumor Quality Control Center of the National Tumor Quality Control Center, and the diagnosis and treatment of malignant lymphoma ( The second edition) "Published. Hosted by the Southern Cancer Specialist Committee of the Chinese Medical Society of the Cancer Branch of the Chinese Medical Association, the China Clinical Oncology Association Rare Tumor Specialist Committee, the Southern Cancer Clinical Research Association, and the "2022 POST-Asco Conference Information Exchange of Information Exchange of Information Exchange of Information Exchange of Information Exchange, The Conference and the Rare Cancer Conference "is the largest academic feast in the field of lymphoma in China.

During the meeting, a reporter from the "Medical Daily" interviewed the chairman of the conference and Professor Lin Tongyu of the Sichuan Cancer Hospital. He expects that cutting -edge studies in the field of lymphoma in the field of lymphoma can enter clinical practice as soon as possible and effectively help patients benefit.

"Medical Daily": What are the highlights of this conference compared with previous conferences?

Professor Lin Tongyu: Since the epidemic of new crown pneumonia in early 2020, this is the first online and offline Chinese lymphoma conference, which was held in the clouds in the past. Experts in the field of lymphoma can emerge from the sparks of more thinking collisions, and face -to -face gathering can be used to discuss the problems and inherit practical experience. Medical needs inheritance to innovate, and unity to develop. Therefore, I think this conference is a conference of "inheritance, innovation, unity, and development."

"Medical Daily": This meeting showed the latest research in various fields of lymphoma. In your opinion, what are the places to pay attention to these studies in clinical practice?

Professor Lin Tongyu: The research displayed in this conference is mainly divided into two categories. One category is research from enterprises. We will pay attention to the efficacy of drugs in clinical trials, and the toxic and side reactions and dosage in Chinese patients. At the same time, we must also consider drug economics. For example, a drug CR rate increased by 74%from 70%, and only a small number of people benefited, while the price of the drug was very expensive.

Another type of research is initiated by researchers. Due to less publicity, these studies generally do not pay enough attention, but many studies have practical significance. For example, a study found that the radiotherapy dose of patients with inert lymphoma requires only 24GY, and no greater dose is required. We expect these research on clinical significance to get more attention in the industry.

"Medical Daily": In your opinion, what are the problems that should be paid attention to when applying abroad to domestic patients?

Professor Lin Tongyu: First, how much efficacy is brought about by research. Second, explore the dose suitable for Chinese patients. Many foreign studies are dominated by Caucasus people, and they are relatively high in dosage application. Third, it is drug economics. China is still a developing country, not so rich, money should be used on the blade. Don't always think of all 1.2 million push push, can it afford it? All Chinese people can afford it. Therefore, we should consider various factors. "Medical Daily": In recent years, the diagnosis and treatment of lymphoma in my country has gradually standardized, but there are still gaps between the three hospitals and grassroots hospitals. How to solve it?

Professor Lin Tongyu: In December last year, the National Tumor Quality Control Center Lymphoma Tumoric Opinification Expert Committee was established to promote the quality specifications of lymphoma diagnosis and treatment and promote the standardization of tumor diagnosis and treatment nationwide. The primary task of our work is to select demonstration units in six major regions across the country to drive the development of each region, realize the standardization, homogeneity, and standardization of lymphoma diagnosis and treatment in my country, and improve the survival rate and quality of life of patients with lymphoma tumors.

The meeting also attaches great importance to the standardization of lymphoma diagnosis and treatment. On July 7, the offline meeting of the National Tumor Quality Control Center's lymphoma special committee was successfully held for the first time, and more than 200 experts contributed suggestions for the standardization of lymphoma diagnosis and treatment in my country. Another major event is that after the joint efforts of more than 200 experts, the "Diagnosis and therapy of Malignant Lympoloma (Second Edition)" was officially published. The level of Chinese lymphoma needs to be continuously advanced and in line with the world to continuously improve the level of diagnosis and treatment of lymphoma in my country.

Capture: Guan Yanqing

Edit: Guan Yanqing

- END -